<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255980</url>
  </required_header>
  <id_info>
    <org_study_id>HD01-16-30</org_study_id>
    <nct_id>NCT03255980</nct_id>
  </id_info>
  <brief_title>Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®</brief_title>
  <official_title>Monocenter, Open Label Clinical Investigation on the Treatment With Xonrid®, a Medical Device for the Prevention and Treatment of Radiotherapy-induced Dermatitis, in Breast and Head &amp; Neck Cancer Patients Receiving Curative Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the performance of Xonrid® in the prevention and treatment of G2 radiation
      dermatitis in breast and head &amp; neck cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>MONOCENTER, OPEN LABEL CLINICAL INVESTIGATION</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients without grade G2 skin toxicity Radiodermatitis at week 5</measure>
    <time_frame>5 weeks over 7 weeks</time_frame>
    <description>Skin toxicity assessed accoriding to CTCAE v4.0 Term Dermatitis Radiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median time to G2 Radiodermatitis development</measure>
    <time_frame>5 weeks over 7 weeks</time_frame>
    <description>Skin toxicity assessed accoriding to CTCAE v4.0 Term Dermatitis Radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients without G2 Radiodermatitis at week 6</measure>
    <time_frame>6 weeks over 7 weeks</time_frame>
    <description>Skin toxicity assessed accoriding to CTCAE v4.0 Term Dermatitis Radiation for both cancer sites, at week 7 for head &amp; neck cancer and 2 weeks after the last radiation for both cancer sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst skin toxicity during treatment and until 2 weeks after the last radiation</measure>
    <time_frame>Follow-up: 2 weeks after the completion of radiation treatment</time_frame>
    <description>Skin toxicity assessed accoriding to CTCAE v4.0 Term Dermatitis Radiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and worst score of Patient Reported Outcome (PRO)</measure>
    <time_frame>weekly during teratment (7 weeks)</time_frame>
    <description>Patient outcome will be collected with Skindex-16 questionnaire performed weekly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to experimental treatment use</measure>
    <time_frame>5 weeks over 7 weeks</time_frame>
    <description>compliance will be calculated trough the weight differences of the Xonrid tubes before and after the use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's treatment global satisfaction</measure>
    <time_frame>5 weeks over 7 weeks</time_frame>
    <description>Patient global satisfaction with treatment as assessed by Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment safety and tolerability</measure>
    <time_frame>6 weeks over 7 weeks</time_frame>
    <description>Adverse events will be coded using the last updated version of the Medical Dictionary for Regulatory Activities (MedDRA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Radiodermatitis</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Xonrid®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xonrid® is a medical device for radiation dermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care suggested by MASCC guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xonrid® gel</intervention_name>
    <description>Water based gel for the management of toxicity skin symptoms induced by Radiotherapy</description>
    <arm_group_label>Xonrid®</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines</description>
    <arm_group_label>Xonrid®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female which are 18 years of age or older

          2. Performance status &lt; 2

          3. Epithelial carcinoma of oropharynx, nasopharynx, larynx, hypopharynx, paranasal sinus
             and salivary glands or breast cancer, planned to receive a total dose of at least 50
             Gy

          4. Postoperative or curative radiation treatment

          5. Concurrent chemotherapy is accepted, in head &amp; neck cancer patients

          6. Patients willing and able to give signed informed consent and, in the opinion of the
             Investigator, to comply with the Clinical Investigation Plan tests and procedures.

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Planned to receive concurrent cetuximab

          3. Previous radiation therapy on the head and neck area or breast and thorax areas

          4. Cutaneous and connective diseases (i.e. lupus erythematosus or scleroderma)

          5. Systemic diseases known to delay the skin healing process such as diabetes mellitus or
             severe renal failure

          6. Use of a tissue-equivalent bolus

          7. Use of over-the-counter topical medications containing steroids

          8. Presence of rashes or unhealed wounds in the radiation field

          9. Recent sun exposure

         10. Mental conditions that could adversely affect patients' adherence to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orlandi Ester, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Orlandi Ester, MD</last_name>
    <phone>0039 02 23903265</phone>
    <email>ester.orlandi@istitutotumori.mi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlandi Ester, MD</last_name>
    </contact>
    <investigator>
      <last_name>Orlkandi Ester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

